{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:10:30Z","timestamp":1780452630989,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41390-019-0541-2","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T18:02:44Z","timestamp":1566410564000},"page":"104-111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation"],"prefix":"10.1038","volume":"87","author":[{"given":"Lynda E.","family":"Polgreen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy C.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Braunlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester B.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B.","family":"Eisengart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Northrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Rudser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weston P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"key":"541_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(81)91046-1","volume":"2","author":"JR Hobbs","year":"1981","unstructured":"Hobbs, J. R. et al. Reversal of clinical features of Hurler\u2019s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2, 709\u2013712 (1981).","journal-title":"Lancet"},{"key":"541_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10545-016-0006-2","volume":"40","author":"NJ Rodgers","year":"2017","unstructured":"Rodgers, N. J. et al. Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience. J. Inherit. Metab. Dis. 40, 271\u2013280 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"541_CR3","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven, M. et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 125, 2164\u20132172 (2015).","journal-title":"Blood"},{"issue":"1","key":"541_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/PRM-2010-0105","volume":"3","author":"Ellen B. Fung","year":"2010","unstructured":"Fung, E. B., Johnson, J. A., Madden, J., Kim, T., Harmatz, P. Bone density assessment in patients with mucopolysaccharidosis: a preliminary report from patients with MPS II and VI. J. Pediatr. Rehabil. Med. 3, 13\u201323 (2010).","journal-title":"Journal of Pediatric Rehabilitation Medicine"},{"key":"541_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/bmt.2008.20","volume":"41","author":"LE Polgreen","year":"2008","unstructured":"Polgreen, L. E. et al. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transpl. 41, 1005\u20131011 (2008).","journal-title":"Bone Marrow Transpl."},{"issue":"11","key":"541_CR6","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.bbadis.2011.07.013","volume":"1812","author":"E. Oussoren","year":"2011","unstructured":"Oussoren, E., Brands, M. M., Ruijter, G. J., der Ploeg, A. T., Reuser, A. J. Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochim. Biophys. Acta 1812, 1542\u20131556 (2011).","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"541_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/01241398-200401000-00019","volume":"24","author":"JS Weisstein","year":"2004","unstructured":"Weisstein, J. S., Delgado, E., Steinbach, L. S., Hart, K. & Packman, S. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J. Pedia. Orthop. 24, 97\u2013101 (2004).","journal-title":"J. Pedia. Orthop."},{"key":"541_CR8","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.4081\/or.2010.e16","volume":"2","author":"B Link","year":"2010","unstructured":"Link, B. et al. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. Orthop. Rev. Pavia 2, e16 (2010).","journal-title":"Orthop. Rev. Pavia"},{"issue":"1","key":"541_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ymgme.2013.03.001","volume":"109","author":"Simon A. Jones","year":"2013","unstructured":"Jones, S. A. et al. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol. Genet. Metab. 109, 41\u20138 (2013).","journal-title":"Molecular Genetics and Metabolism"},{"issue":"11","key":"541_CR10","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/gim.2018.29","volume":"20","author":"Julie B Eisengart","year":"2018","unstructured":"Eisengart, J. et al. Long-term outcomes of systemic therapies for Hurler syndrome: an international multi-center comparison. Genet. Med. 20, 1423\u20131429 (2018)","journal-title":"Genetics in Medicine"},{"key":"541_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","volume":"117","author":"A Ghosh","year":"2016","unstructured":"Ghosh, A. et al. Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10 year combined experience of 2 centres. Mol. Genet. Metab. 117, 373\u2013377 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"541_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/00004703-200608000-00002","volume":"27","author":"KJ Bjoraker","year":"2006","unstructured":"Bjoraker, K. J., Delaney, K., Peters, C., Krivit, W. & Shapiro, E. G. Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation. J. Dev. Behav. Pedia. 27, 290\u2013296 (2006).","journal-title":"J. Dev. Behav. Pedia."},{"key":"541_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ymgme.2012.07.016","volume":"107","author":"E Shapiro","year":"2012","unstructured":"Shapiro, E. et al. An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT). Mol. Genet. Metab. 107, 116\u2013121 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"541_CR14","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/blood.V91.7.2601","volume":"91","author":"C Peters","year":"1998","unstructured":"Peters, C. et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 91, 2601\u20132608 (1998).","journal-title":"Blood"},{"key":"541_CR15","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1182\/blood.V87.11.4894.bloodjournal87114894","volume":"87","author":"C Peters","year":"1996","unstructured":"Peters, C. et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 87, 4894\u20134902 (1996).","journal-title":"Blood"},{"key":"541_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jpeds.2012.07.052","volume":"162","author":"JB Eisengart","year":"2013","unstructured":"Eisengart, J. B. et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J. Pedia. 162, 375\u2013380 (2013). e1.","journal-title":"J. Pedia."},{"key":"541_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/ana.24246","volume":"76","author":"MD Poe","year":"2014","unstructured":"Poe, M. D., Chagnon, S. L. & Escolar, M. L. Early treatment is associated with improved cognition in Hurler syndrome. Ann. Neurol. 76, 747\u2013753 (2014).","journal-title":"Ann. Neurol."},{"key":"541_CR18","first-page":"1108","volume":"97","author":"G Malm","year":"2008","unstructured":"Malm, G. et al. Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT). Acta Paediatr. Oslo Nor. 1992 97, 1108\u20131112 (2008).","journal-title":"Acta Paediatr. Oslo Nor. 1992"},{"key":"541_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01.GIM.0000154299.22120.6A","volume":"7","author":"SS Grewal","year":"2005","unstructured":"Grewal, S. S. et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet. Med. 7, 143\u2013146 (2005).","journal-title":"Genet. Med."},{"key":"541_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ymgmr.2014.12.006","volume":"2","author":"E Yasuda","year":"2015","unstructured":"Yasuda, E. et al. Molecular Genetics and Metabolism Report Long-term follow-up of post hematopoietic stem cell transplantation for Hurler syndrome: clinical, biochemical, and pathological improvements. Mol. Genet. Metab. Rep. 2, 65\u201376 (2015).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"541_CR21","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","volume":"121","author":"JJ Boelens","year":"2013","unstructured":"Boelens, J. J. et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 121, 3981\u20133987 (2013).","journal-title":"Blood"},{"key":"541_CR22","unstructured":"Kunin-Batson, A. S. et al. Long-term cognitive and functional outcomes in children with mucopolysaccharidosis (MPS)-IH (Hurler Syndrome) treated with hematopoietic cell transplantation. JIMD Rep. 29, 95\u2013102 (2016)."},{"key":"541_CR23","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","volume":"116","author":"I Visigalli","year":"2010","unstructured":"Visigalli, I. et al. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116, 5130\u20135139 (2010).","journal-title":"Blood"},{"key":"541_CR24","first-page":"353","volume":"7","author":"NE Taylor","year":"2014","unstructured":"Taylor, N. E. et al. Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI. J. Pedia. Rehabil. Med. 7, 353\u2013360 (2014).","journal-title":"J. Pedia. Rehabil. Med."},{"key":"541_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ymgme.2013.11.013","volume":"111","author":"LE Polgreen","year":"2014","unstructured":"Polgreen, L. E., Thomas, W., Orchard, P. J., Whitley, C. B. & Miller, B. S. Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome. Mol. Genet. Metab. 111, 101\u2013106 (2014).","journal-title":"Mol. Genet. Metab."},{"key":"541_CR26","first-page":"159","volume":"7","author":"DA Stevenson","year":"2014","unstructured":"Stevenson, D. A. et al. Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. J. Pedia. Rehabil. Med. 7, 159\u2013165 (2014).","journal-title":"J. Pedia. Rehabil. Med."},{"key":"541_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","volume":"117","author":"Y Xue","year":"2016","unstructured":"Xue, Y., Richards, S. M., Mahmood, A. & Cox, G. F. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies. Mol. Genet. Metab. 117, 419\u2013426 (2016).","journal-title":"Mol. Genet. Metab."},{"key":"541_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0255-4","volume":"10","author":"AR Pal","year":"2015","unstructured":"Pal, A. R. et al. Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Orphanet. J. Rare Dis. 10, 42 (2015).","journal-title":"Orphanet. J. Rare Dis."},{"key":"541_CR29","unstructured":"Rowland, T. Pediatric Laboratory Exercise Testing Champaing. Illinois: Human Kinetics Europe Ltd.; 1993."},{"key":"541_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.","year":"2002","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 166, 111\u2013117 (2002).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"541_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke, L. A. et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 123, 229\u2013240 (2009).","journal-title":"Pediatrics"},{"key":"541_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith, J. E. et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J. Pedia. 144, 581\u2013588 (2004).","journal-title":"J. Pedia."},{"key":"541_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jpeds.2016.08.033","volume":"178","author":"S Laraway","year":"2016","unstructured":"Laraway, S. et al. Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I. J. Pedia. 178, 219\u2013226.e1 (2016).","journal-title":"J. Pedia."},{"key":"541_CR34","unstructured":"Kuczmarski, R. J. et al. CDC growth charts: United States. Adv. Data 8, 1\u201327 (2000)."},{"key":"541_CR35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.echo.2010.03.019","volume":"23","author":"L Lopez","year":"2010","unstructured":"Lopez, L. et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J. Am. Soc. Echocardiogr. Publ. Am. Soc. Echocardiogr. 23, 465\u2013495 (2010). quiz576\u20137.","journal-title":"J. Am. Soc. Echocardiogr. Publ. Am. Soc. Echocardiogr."},{"key":"541_CR36","unstructured":"Team RDC. R: A Language and Environment for Statistical Computing [Internet]. (R Foundation for Statistical Computing, Vienna, 2011). \nhttp:\/\/www.R-project.org\/"},{"key":"541_CR37","unstructured":"Schmidt, M. et al. Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation. Orphanet. J. Rare Dis. [Internet]. 11 (2016). \nhttp:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4938899\/"},{"key":"541_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis, E. D. et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344, 182\u2013188 (2001).","journal-title":"N. Engl. J. Med."},{"key":"541_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes, M. et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol. Genet. Metab. 90, 171\u2013180 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"541_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymgmr.2017.01.002","volume":"10","author":"LE Polgreen","year":"2017","unstructured":"Polgreen, L. E. et al. Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II. Mol. Genet. Metab. Rep. 10, 75\u201380 (2017).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"541_CR41","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1161\/01.CIR.90.4.2166","volume":"90","author":"RL Washington","year":"1994","unstructured":"Washington, R. L. et al. Guidelines for exercise testing in the pediatric age group. From the Committee on Atherosclerosis and Hypertension in Children, Council on Cardiovascular Disease in the Young, the American Heart Association. Circulation 90, 2166\u20132179 (1994).","journal-title":"Circulation"},{"key":"541_CR42","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3324\/haematol.2011.058644","volume":"97","author":"MA Saif","year":"2012","unstructured":"Saif, M. A. et al. Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler\u2019s syndrome after pharmacological enzyme replacement therapy. Haematologica 97, 1320\u20131328 (2012).","journal-title":"Haematologica"},{"key":"541_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ymgme.2014.10.012","volume":"114","author":"EJ Langereis","year":"2015","unstructured":"Langereis, E. J. et al. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy. Mol. Genet. Metab. 114, 129\u2013137 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"541_CR44","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0002-9149(03)00909-3","volume":"92","author":"EA Braunlin","year":"2003","unstructured":"Braunlin, E. A. et al. Usefulness of bone marrow transplantation in the Hurler syndrome. Am. J. Cardiol. 92, 882\u2013886 (2003).","journal-title":"Am. J. Cardiol."},{"key":"541_CR45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.amjcard.2006.02.047","volume":"98","author":"EA Braunlin","year":"2006","unstructured":"Braunlin, E. A., Berry, J. M. & Whitley, C. B. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am. J. Cardiol. 98, 416\u2013418 (2006).","journal-title":"Am. J. Cardiol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41390-019-0541-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-019-0541-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-019-0541-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:27:48Z","timestamp":1684618068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-019-0541-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1038\/s41390-019-0541-2","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"15 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.E.P. is a speaker and consultant for Sanofi\/Genzyme, receives research support from Sanofi\/Genzyme and Shire, and is a consultant for Sangamo. T.C.L. receives research support from Sanofi\/Genzyme. E.B. is a speaker for Sanofi\/Genzyme and receives research support from BioMarin and Bluebird Bio. B.S.M. is a consultant for AbbVie, Ascendis, Ferring, Novo Nordisk, Pfizer, Sandoz and Versartis and has received research support from Alexion, Ascendis, Endo Pharmaceuticals, Genentech, Genzyme, Novo Nordisk, Opko, Sandoz, Sangamo, Shire, Tolmar and Versartis. E.F. is a consultant for BioMarin Pharmaceuticals. C.B.W. is a consultant for Sanofi\/Genzyme. J.B.E. has received honoraria, consulting fees, and\/or research support from ArmaGen, Regenexbio, Sangamo, and Sanofi\/Genzyme, and has done contract work for Shapiro Neuropsychology Consulting, LLC. W.P.M. is an employee of Sangamo Therapeutics. P.J.O. receives research and clinical trial support from Sanofi\/Genzyme, Horizon, Magenta and Bluebird Bio. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}